Among the most promising targeted therapies, Rapamycin, an mTOR inhibitor that targets the KS paracrine oncogenesis axis and the multi-kinase inhibitor Imatinib which targets PDGFRA, c-kit and c-abl showed some responses in transplant [67] and AIDS-KS [68] respectively. This evidence concerns the gene MTOR and Kaposi's sarcoma.